Dexmedetomidine EQL Pharma: Uses, Dosage & Side Effects
A highly selective alpha-2 adrenergic agonist for sedation of adult ICU patients requiring light to moderate sedation with maintained arousability
Dexmedetomidine EQL Pharma is a prescription sedative used in intensive care units (ICUs) for adult patients who require light to moderate sedation. Containing the active ingredient dexmedetomidine hydrochloride at a concentration of 100 micrograms per milliliter, this concentrate for solution for infusion works by activating alpha-2 adrenergic receptors in the brainstem to produce a unique form of cooperative sedation that mimics natural sleep. Unlike traditional sedatives such as propofol or midazolam, dexmedetomidine allows patients to remain arousable and capable of participating in neurological assessments while providing concurrent analgesic and anxiolytic effects. It is administered exclusively by healthcare professionals in monitored hospital settings via continuous intravenous infusion.
Quick Facts: Dexmedetomidine EQL Pharma
Key Takeaways
- Dexmedetomidine EQL Pharma is a highly selective alpha-2 adrenergic agonist used for sedation of adult ICU patients who require a sedation level no deeper than arousal in response to verbal stimulation (RASS 0 to -3).
- Unlike GABAergic sedatives (propofol, midazolam), dexmedetomidine produces cooperative sedation that mimics natural sleep, allowing patients to be easily aroused for neurological assessments without significant respiratory depression.
- The most common side effects are bradycardia and hypotension (occurring in over 10% of patients), requiring continuous cardiac and hemodynamic monitoring throughout the infusion.
- Dexmedetomidine provides concurrent analgesic and anxiolytic effects, potentially reducing the need for opioids and benzodiazepines in the ICU setting, and has been associated with lower rates of delirium compared to traditional sedatives.
- The concentrate (100 mcg/ml) must be diluted before intravenous infusion, typically to a concentration of 4 mcg/ml, and is administered at maintenance rates of 0.2 to 1.4 mcg/kg/hour by trained healthcare professionals in a monitored environment.
What Is Dexmedetomidine EQL Pharma and What Is It Used For?
Dexmedetomidine EQL Pharma contains the active substance dexmedetomidine hydrochloride, the pharmacologically active dextro-enantiomer of medetomidine. It belongs to a class of medications known as alpha-2 adrenergic receptor agonists and is specifically designed for use in intensive care medicine. Dexmedetomidine was first synthesized in the 1980s and was originally approved by the U.S. Food and Drug Administration (FDA) in 1999 under the brand name Precedex for short-term sedation of mechanically ventilated patients in the ICU. It has since gained approval in the European Union and over 70 countries worldwide, with EQL Pharma producing a generic formulation that provides the same clinical benefits as the originator product.
The primary indication for dexmedetomidine is sedation of adult ICU patients who require a sedation level no deeper than arousal in response to verbal stimulation. This corresponds to a Richmond Agitation-Sedation Scale (RASS) score of 0 to -3, where 0 represents an alert and calm state and -3 represents moderate sedation with movement or eye opening to voice but no eye contact. This targeted sedation level is increasingly recognized as optimal for most ICU patients, as deeper levels of sedation have been associated with prolonged mechanical ventilation, increased ICU length of stay, and higher rates of cognitive complications including delirium.
What makes dexmedetomidine unique among ICU sedatives is its mechanism of action. While the most commonly used sedatives in intensive care—propofol and midazolam—act primarily through potentiation of gamma-aminobutyric acid (GABA) receptor activity, dexmedetomidine works through a fundamentally different pathway. It acts on alpha-2 adrenergic receptors in the locus coeruleus, the principal noradrenergic nucleus of the brainstem that regulates wakefulness and sleep. By activating these receptors, dexmedetomidine inhibits norepinephrine release from locus coeruleus neurons, effectively engaging the endogenous sleep-promoting pathway. This produces a state of sedation that closely resembles stage 2 non-rapid eye movement (NREM) sleep, from which patients can be easily aroused by verbal or gentle physical stimulation.
This sleep-like sedation profile has important clinical implications. Patients sedated with dexmedetomidine can be readily awakened for neurological examinations, communication with family members and healthcare providers, and participation in early mobilization programs—all of which are increasingly recognized as critical components of optimal ICU care. The ability to maintain this cooperative sedation while still providing meaningful anxiolysis and analgesia distinguishes dexmedetomidine from other available options. Studies have consistently shown that dexmedetomidine reduces the requirement for supplemental opioid analgesia by 30-50% compared with placebo, which can contribute to reduced opioid-related side effects such as ileus, nausea, and respiratory depression.
Beyond its role as a primary sedative, dexmedetomidine has found applications in procedural sedation for non-intubated patients, as an adjunct to general anesthesia (reducing anesthetic and opioid requirements), for shivering prevention after surgery, and in the management of alcohol and substance withdrawal syndromes. The PADIS guidelines published by the Society of Critical Care Medicine in 2018 conditionally recommend either propofol or dexmedetomidine over benzodiazepines for sedation in critically ill adults, citing evidence of improved outcomes including shorter time to extubation and lower delirium prevalence with non-benzodiazepine sedation strategies.
Dexmedetomidine is the only ICU sedative that activates the brain's natural sleep pathway (via alpha-2 receptors in the locus coeruleus), producing cooperative sedation from which patients can be easily aroused. This unique property allows patients to participate in daily sedation interruption trials, spontaneous breathing trials, and early mobilization protocols without requiring complete discontinuation of the sedative infusion.
What Should You Know Before Taking Dexmedetomidine EQL Pharma?
Contraindications
The primary contraindication to dexmedetomidine use is known hypersensitivity to dexmedetomidine hydrochloride or to any of the excipients contained in the formulation. Dexmedetomidine EQL Pharma contains sodium chloride and water for injections as excipients, and the pH is adjusted with hydrochloric acid and/or sodium hydroxide. While anaphylactic reactions to dexmedetomidine are rare, they have been reported in post-marketing surveillance and include urticaria, angioedema, hypotension, and bronchospasm.
Dexmedetomidine should not be used as a sole sedative agent when deep sedation is required (RASS -4 to -5), as it is not designed to produce or maintain this level of sedation reliably. Patients who require deep sedation, such as those with severe acute respiratory distress syndrome (ARDS) requiring neuromuscular blockade or those undergoing prone positioning that necessitates deep sedation, should receive alternative sedative agents. Additionally, dexmedetomidine is contraindicated in patients with advanced heart block (second or third degree) in the absence of a pacemaker, as the drug's vagomimetic and sympatholytic effects can further suppress atrioventricular conduction and exacerbate bradyarrhythmias.
Warnings and Precautions
Dexmedetomidine can cause clinically significant bradycardia and hypotension, which may require intervention. Continuous ECG, blood pressure, and heart rate monitoring is mandatory throughout the infusion and for a period after discontinuation. Have atropine, vasopressors, and resuscitation equipment immediately available. Transient hypertension may also occur, particularly during loading dose administration.
Healthcare professionals administering dexmedetomidine should be aware of and prepared to manage the following clinical considerations:
- Bradycardia and cardiac arrest: Dexmedetomidine decreases heart rate through both central sympatholytic effects and enhanced vagal activity. Clinically significant bradycardia, including sinus arrest and complete heart block, has been reported. Risk factors include baseline slow heart rate, concurrent use of other negative chronotropic agents (beta-blockers, digoxin, calcium channel blockers), young age, and high physical fitness. Atropine and glycopyrrolate may not be fully effective in treating dexmedetomidine-induced bradycardia; isoproterenol or temporary pacing may be required in refractory cases.
- Hypotension: Blood pressure reduction occurs through decreased central sympathetic outflow and peripheral vasodilation. Patients who are hypovolemic, have impaired autonomic function, or are receiving concurrent vasodilators or antihypertensive medications are at increased risk. Volume status should be optimized before initiating dexmedetomidine, and vasopressor support should be readily available.
- Transient hypertension: A biphasic hemodynamic response is characteristic of dexmedetomidine. During initial loading or with rapid increases in infusion rate, transient hypertension may occur due to peripheral alpha-2B receptor activation causing vasoconstriction. This is typically followed by a sustained reduction in blood pressure. The loading dose is often omitted or administered slowly to minimize this effect.
- Hepatic impairment: Dexmedetomidine is extensively metabolized by the liver. Patients with severe hepatic impairment (Child-Pugh class C) have significantly reduced clearance and should receive reduced doses with careful titration. Moderate hepatic impairment (Child-Pugh class B) may also require dose adjustment.
- Renal impairment: While dexmedetomidine metabolites are primarily excreted renally, dose adjustment is generally not required in patients with renal impairment, as the metabolites are pharmacologically inactive. However, caution is advised in patients with severe renal impairment, as limited data are available in this population.
Pregnancy and Breastfeeding
There are limited data on the use of dexmedetomidine in pregnant women. Animal reproductive studies have shown that dexmedetomidine crosses the placenta and has demonstrated reduced fetal body weight and delayed ossification at high doses in rats, though no teratogenic effects were observed. Dexmedetomidine should be used during pregnancy only when the potential benefit to the mother justifies the potential risk to the fetus, and typically only in critical care situations where no safer alternative is available.
Dexmedetomidine and/or its metabolites are excreted in rat milk, and it is likely that dexmedetomidine passes into human breast milk. Given the drug's pharmacological properties, breastfed infants should be monitored for potential effects including excessive sedation and poor feeding. A decision should be made whether to discontinue breastfeeding or to discontinue dexmedetomidine therapy during the infusion period, taking into account the benefit of breastfeeding for the infant and the benefit of therapy for the mother. Breast milk expressed during the infusion and for 24 hours after discontinuation should be discarded as a precautionary measure.
Children and Adolescents
Dexmedetomidine EQL Pharma is not approved for use in children and adolescents under 18 years of age for ICU sedation. The safety and efficacy of dexmedetomidine have not been formally established in the pediatric population for this indication, and clinical data remain limited. Pediatric patients demonstrate age-dependent pharmacokinetic differences, with neonates and infants showing higher volume of distribution and longer elimination half-lives compared to older children and adults. Off-label pediatric use does occur in specialist centers, but dosing, efficacy, and safety data are derived primarily from small observational studies and should be interpreted with caution. Any use in pediatric patients should be under specialist guidance with appropriate monitoring.
How Does Dexmedetomidine EQL Pharma Interact with Other Drugs?
Dexmedetomidine is metabolized primarily through direct glucuronidation (mediated by UGT2B10 and UGT1A4) and cytochrome P450-mediated oxidation (predominantly CYP2A6, with minor contributions from CYP1A2, CYP2D6, CYP2E1, and CYP2C19). In vitro studies suggest that dexmedetomidine neither inhibits nor induces cytochrome P450 enzymes at clinically relevant concentrations, and therefore pharmacokinetic drug-drug interactions through CYP-mediated metabolism are not expected to be clinically significant. However, the pharmacodynamic interactions of dexmedetomidine with other central nervous system depressants and cardiovascular agents are clinically important and require careful attention.
Major Interactions
| Drug/Class | Interaction | Clinical Significance |
|---|---|---|
| Propofol | Additive sedation and respiratory depression; enhanced hypotensive effect | Reduce propofol dose by 20-40% when co-administered; closely monitor hemodynamics and sedation depth |
| Opioids (fentanyl, morphine, remifentanil) | Synergistic sedation and analgesia; additive bradycardia and respiratory depression | Reduce opioid dose by 30-50%; monitor respiratory rate, sedation level, and heart rate continuously |
| Benzodiazepines (midazolam, diazepam) | Additive sedation; prolonged time to recovery from sedation | Reduce benzodiazepine dose; assess sedation depth frequently using validated scales |
| Beta-blockers, calcium channel blockers | Additive bradycardia and hypotension; risk of severe hemodynamic compromise | High risk of clinically significant bradycardia; have atropine and pacing equipment available |
| Volatile anesthetics (sevoflurane, isoflurane) | Reduces MAC (minimum alveolar concentration) by up to 90%; enhanced hypotension | Significantly reduce volatile agent concentration when transitioning from or to dexmedetomidine |
Minor Interactions
| Drug/Class | Interaction | Clinical Significance |
|---|---|---|
| Neuromuscular blocking agents | No pharmacokinetic interaction; dexmedetomidine does not alter neuromuscular blockade duration | Safe to use concurrently; no dose adjustment needed for neuromuscular blockers |
| Vasopressors (norepinephrine, vasopressin) | May partially counteract dexmedetomidine-induced hypotension; interaction is generally manageable | Monitor blood pressure; vasopressor requirements may increase during dexmedetomidine infusion |
| Digoxin | Additive AV nodal depression; potential for enhanced bradycardia | Monitor heart rate and ECG; particular caution in elderly patients with existing conduction abnormalities |
| Anticholinesterase inhibitors (neostigmine) | Theoretical risk of enhanced bradycardia | Monitor heart rate when administering reversal agents during recovery from neuromuscular blockade |
It is important to note that the interaction profile of dexmedetomidine is primarily pharmacodynamic rather than pharmacokinetic. The drug's sedative, analgesic, and hemodynamic effects are enhanced when combined with other agents that share these properties. In the ICU setting, polypharmacy is the norm, and careful titration of all sedative, analgesic, and cardiovascular agents is essential. The treating physician should consider the cumulative effects of all medications on sedation depth, respiratory function, heart rate, and blood pressure when adjusting dexmedetomidine dosing.
What Is the Correct Dosage of Dexmedetomidine EQL Pharma?
Dexmedetomidine EQL Pharma is supplied as a concentrate for solution for infusion at a concentration of 100 micrograms per milliliter. This concentrate must be diluted before intravenous administration. The standard preparation involves diluting 2 ml of the concentrate (200 mcg) in 48 ml of 0.9% sodium chloride (normal saline) to yield a final concentration of 4 micrograms per milliliter in a total volume of 50 ml. Alternatively, 5% glucose (dextrose) solution may be used as the diluent. The diluted solution should be gently mixed and inspected visually for particulate matter and discoloration before administration. It should be used within 24 hours of preparation.
Adults
Standard ICU Sedation – Adults
Loading dose (optional): 1 microgram per kilogram body weight, infused over 10 to 20 minutes. The loading dose is frequently omitted or reduced (0.5 mcg/kg) to minimize the risk of transient hypertension and bradycardia. It is particularly important to omit or reduce the loading dose in patients who are hypovolemic, hypotensive, or have significant cardiac conduction abnormalities.
Maintenance infusion: 0.2 to 1.4 micrograms per kilogram per hour. The infusion rate should be titrated individually to the desired clinical effect using a validated sedation assessment tool such as the Richmond Agitation-Sedation Scale (RASS). The target sedation level is typically RASS 0 to -3.
Duration: No maximum duration is specified in the EU SmPC, but the majority of clinical trial evidence supports use for up to 14 days. The FDA-approved labeling for the originator product (Precedex) specifies use for up to 24 hours. Extended use beyond 24 hours is common in clinical practice and is supported by observational data and some randomized trials.
| Patient Group | Loading Dose | Maintenance Rate | Special Considerations |
|---|---|---|---|
| Standard adult | 0.5–1 mcg/kg over 10–20 min (optional) | 0.2–1.4 mcg/kg/hr | Titrate to RASS target; start low and increase gradually |
| Elderly (≥65 years) | Consider omitting or 0.5 mcg/kg | 0.2–0.7 mcg/kg/hr | Increased sensitivity; higher risk of bradycardia and hypotension |
| Hepatic impairment | Consider omitting | Reduce dose; titrate carefully | Reduced clearance in severe impairment; monitor for oversedation |
| Renal impairment | Standard | 0.2–1.4 mcg/kg/hr | No dose adjustment generally required; metabolites are inactive |
| Post-cardiac surgery | Often omitted | 0.2–0.7 mcg/kg/hr initially | Close hemodynamic monitoring; common co-use with beta-blockers and amiodarone |
Children
Dexmedetomidine EQL Pharma is not approved for pediatric use. There is no established dosing regimen for children and adolescents under 18 years of age for ICU sedation. Off-label use in pediatric patients has been reported in the literature, with typical maintenance infusion rates of 0.2 to 1.0 mcg/kg/hour in children aged 1 month to 17 years, but these data come from small studies and the safety profile in this population has not been comprehensively characterized. Neonates and infants may require different dosing approaches due to immature hepatic metabolism and higher volume of distribution. Any pediatric use should be under specialist guidance.
Elderly
Elderly patients (65 years and older) demonstrate increased sensitivity to dexmedetomidine and are at higher risk of bradycardia and hypotension. This is attributable to age-related changes in cardiovascular physiology, including reduced baroreceptor reflex sensitivity, decreased cardiac output reserve, and increased prevalence of conduction system disease. The loading dose should be reduced or omitted in elderly patients, and maintenance infusion rates should be started at the lower end of the dosing range (0.2 mcg/kg/hr) with cautious upward titration. A maximum maintenance rate of 0.7 mcg/kg/hr is generally recommended for elderly patients, although individual responses vary. Careful hemodynamic monitoring and frequent sedation assessments are particularly important in this population.
Missed Dose
As dexmedetomidine is administered as a continuous intravenous infusion by healthcare professionals in a monitored setting, the concept of a missed dose does not apply in the traditional sense. If the infusion is inadvertently interrupted or discontinued, the treating physician will assess the patient's sedation level and hemodynamic status and determine whether to restart the infusion. Due to the drug's relatively short elimination half-life (approximately 2 hours), the effects of dexmedetomidine diminish fairly rapidly after discontinuation, and patients may become agitated or hypertensive if the infusion is abruptly stopped after prolonged use. Gradual tapering of the infusion rate rather than abrupt discontinuation is recommended to minimize withdrawal phenomena.
Overdose
Overdose of dexmedetomidine may result in exaggerated pharmacological effects, primarily deep sedation, marked bradycardia, hypotension, and in severe cases, cardiac arrest. There is no specific antidote for dexmedetomidine. Management of overdose is supportive and symptom-directed. For bradycardia, atropine (0.5-1 mg IV) or glycopyrrolate may be administered, and in refractory cases, isoproterenol infusion or temporary cardiac pacing may be necessary. Hypotension should be treated with intravenous fluid administration, Trendelenburg positioning, and vasopressor support (norepinephrine or phenylephrine) as needed. The infusion should be immediately discontinued, and the patient should be monitored in an intensive care setting until the effects have fully resolved. Due to dexmedetomidine's extensive protein binding (~94%), dialysis is unlikely to be effective in enhancing drug elimination.
What Are the Side Effects of Dexmedetomidine EQL Pharma?
Like all medicines, dexmedetomidine can cause side effects, although not everybody gets them. The side effect profile of dexmedetomidine is predominantly cardiovascular, reflecting its mechanism of action on alpha-2 adrenergic receptors that modulate sympathetic nervous system activity and cardiac function. Most side effects are dose-dependent and can be managed through careful dose titration and proactive hemodynamic monitoring. The following side effects have been reported in clinical trials and post-marketing surveillance:
Very Common
Affects more than 1 in 10 patients (>10%)
- Hypotension – low blood pressure due to central sympatholytic effects and vasodilation; occurs in approximately 25-30% of patients in clinical trials
- Bradycardia – slow heart rate due to enhanced vagal tone and reduced sympathetic drive; reported in approximately 13-15% of patients
Common
Affects 1 to 10 in 100 patients (1–10%)
- Hyperglycemia – elevated blood sugar, possibly related to stress response modulation
- Hypoglycemia – low blood sugar
- Agitation – may occur during initial titration or if sedation target is not achieved
- Cardiac ischemia or myocardial infarction – related to hemodynamic changes, particularly in patients with pre-existing coronary disease
- Tachycardia – sometimes seen as rebound effect after discontinuation
- Hypertension – transient, typically during loading dose due to peripheral alpha-2B activation
- Dry mouth – due to reduced salivary gland secretion via sympatholytic effects
- Nausea
- Vomiting
- Respiratory depression – usually mild; clinically significant respiratory depression is less common than with opioids or benzodiazepines
Uncommon
Affects 1 to 10 in 1,000 patients (0.1–1%)
- Metabolic acidosis
- Hypoalbuminemia
- Atrioventricular block (1st degree)
- Cardiac output decreased
- Abdominal distension
- Thirst
- Hyperthermia – elevated body temperature
- Drug withdrawal syndrome – after prolonged use (>7 days)
- Drug ineffective – tolerance development with prolonged use
Rare
Affects fewer than 1 in 1,000 patients (<0.1%)
- Cardiac arrest – reported rarely, typically in patients with pre-existing cardiac conditions or those receiving concurrent negative chronotropic agents
- Sinus arrest
- Complete heart block
- Polyuria – increased urine output
Not Known
Frequency cannot be estimated from available data
- Anaphylaxis – severe allergic reaction (reported in post-marketing surveillance)
- Adrenal insufficiency – with prolonged use; clinical significance under investigation
Healthcare staff monitoring a patient on dexmedetomidine should immediately address and report: heart rate below 40 beats per minute, systolic blood pressure below 80 mmHg, signs of cardiac ischemia (ST changes on ECG), respiratory rate below 8 breaths per minute, or any signs of allergic reaction. These events may require dose reduction, infusion discontinuation, and/or pharmacological intervention.
It is important to note that many of the cardiovascular side effects of dexmedetomidine are predictable extensions of its pharmacological action and are manageable through careful dose titration. The MIDEX and PRODEX trials, which compared dexmedetomidine to midazolam and propofol respectively in long-term ICU sedation, found that while dexmedetomidine was associated with more bradycardia and hypotension, it was also associated with a shorter time to extubation, improved patient communication ability, and a trend toward reduced delirium rates. These findings suggest that the overall clinical benefit-risk profile of dexmedetomidine is favorable when used appropriately in the indicated patient population with proper monitoring.
How Should You Store Dexmedetomidine EQL Pharma?
Dexmedetomidine EQL Pharma concentrate for solution for infusion requires specific storage conditions to maintain its stability and potency. Unopened vials should be stored at temperatures below 25°C (77°F) in the original packaging to protect the contents from light. The concentrate must not be frozen, as freezing may alter the physical properties of the solution and potentially affect drug stability.
Once the concentrate has been diluted for intravenous administration (typically to a concentration of 4 mcg/ml in 0.9% sodium chloride or 5% glucose), chemical and physical in-use stability has been demonstrated for 24 hours at 25°C. From a microbiological point of view, the diluted product should be used immediately after preparation. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the healthcare professional and would normally not be longer than 24 hours at 2-8°C (refrigerated), unless dilution has taken place in controlled and validated aseptic conditions.
Healthcare professionals should inspect the diluted solution visually for particulate matter and discoloration before administration. Only clear, colorless solutions without visible particles should be used. Any unused product or waste material should be disposed of in accordance with local regulations for pharmaceutical waste. Patients and family members in a home care context are unlikely to encounter this medication, as it is almost exclusively used in hospital and ICU settings; however, the general principle of keeping all medicines out of the sight and reach of children applies.
Do not use Dexmedetomidine EQL Pharma after the expiry date stated on the vial and carton. The expiry date refers to the last day of that month. Return any expired or unused medication to a pharmacy for proper disposal. Do not dispose of medications in wastewater or household waste, as this may contaminate the environment.
What Does Dexmedetomidine EQL Pharma Contain?
Dexmedetomidine EQL Pharma is a sterile, non-pyrogenic concentrate for solution for infusion supplied in clear glass vials. The formulation has been designed to be simple and contains minimal excipients, reflecting the need for compatibility with a wide range of intravenous administration systems and co-administered medications commonly used in the ICU setting.
Active substance: Each milliliter of concentrate contains 100 micrograms of dexmedetomidine (equivalent to 118 micrograms of dexmedetomidine hydrochloride). Dexmedetomidine is the pharmacologically active S-enantiomer of medetomidine, a well-characterized imidazole compound. It has a molecular formula of C13H16N2·HCl and a molecular weight of approximately 236.7 g/mol for the hydrochloride salt. The free base is a white to off-white powder that is freely soluble in water, and the hydrochloride salt formulation provides excellent aqueous stability.
Other ingredients (excipients):
- Sodium chloride – used to adjust the tonicity of the solution to near-physiological osmolality, making it compatible with intravenous administration and reducing the risk of irritation at the injection site.
- Water for injections – the solvent vehicle, meeting pharmacopoeial standards for sterility and pyrogen content.
- Hydrochloric acid and/or sodium hydroxide – used as pH adjusters to maintain the solution within the optimal stability range (pH 4.5 to 7.0).
Dexmedetomidine EQL Pharma does not contain preservatives, antimicrobial agents, latex, or any components derived from animal sources. The product is gluten-free and does not contain sucrose or lactose. The sodium content per dose is generally low but should be considered in patients on severely sodium-restricted diets receiving high volumes of diluted solution. Healthcare professionals should note that the concentrate is not suitable for direct intravenous injection without dilution and must be prepared according to the dilution instructions provided in the product information before use.
The product is available in 2 ml glass vials (containing 200 micrograms of dexmedetomidine) and 4 ml glass vials (containing 400 micrograms of dexmedetomidine). Not all pack sizes may be marketed in every country. The glass vials are fitted with rubber stoppers and aluminum crimp seals with flip-off caps. Compatibility with common intravenous infusion sets made of natural rubber, polyvinyl chloride, or polyethylene has been demonstrated.
Frequently Asked Questions About Dexmedetomidine EQL Pharma
Dexmedetomidine and propofol are both widely used for ICU sedation but work through fundamentally different mechanisms. Propofol acts on GABA receptors to produce dose-dependent sedation ranging from light sedation to general anesthesia, while dexmedetomidine acts on alpha-2 adrenergic receptors to produce a natural sleep-like state from which patients can be easily aroused. Key clinical differences include: dexmedetomidine causes less respiratory depression and allows cooperative sedation; propofol provides deeper sedation when needed and has a faster onset. Dexmedetomidine is associated with more bradycardia and hypotension, while propofol is associated with more respiratory depression and, with prolonged high-dose use, propofol infusion syndrome. The PADIS guidelines consider both agents appropriate first-line options for ICU sedation over benzodiazepines.
Several studies have suggested that dexmedetomidine may reduce the prevalence and duration of delirium in ICU patients compared to other sedatives, particularly benzodiazepines. The MIDEX trial showed shorter time to extubation and better communication ability with dexmedetomidine compared to midazolam. The DahLIA trial demonstrated that dexmedetomidine resolved ICU delirium faster than placebo in patients with agitated delirium. However, the large SPICE III trial found no significant difference in 90-day mortality between dexmedetomidine and usual care (predominantly propofol), though dexmedetomidine patients had more delirium-free and coma-free days. Current evidence supports dexmedetomidine as a reasonable choice when delirium prevention or treatment is a clinical priority, but it should not be considered a definitive anti-delirium agent.
While the primary approved indication for dexmedetomidine is ICU sedation, it is increasingly used for procedural sedation in various settings including the operating room, endoscopy suites, catheterization laboratories, and radiology departments. Its ability to provide sedation without significant respiratory depression makes it particularly useful for procedures requiring maintained spontaneous ventilation, such as awake fiberoptic intubation, awake craniotomy, and procedures in patients with difficult airways. However, healthcare professionals should note that this use may be considered off-label depending on the specific regulatory approval in their jurisdiction, and the same requirements for hemodynamic monitoring and availability of resuscitation equipment apply.
Abrupt discontinuation of dexmedetomidine after prolonged use (generally more than 7 days) can lead to a withdrawal syndrome characterized by agitation, anxiety, tachycardia, hypertension, tremors, and diaphoresis (excessive sweating). These symptoms are thought to result from a sudden increase in sympathetic nervous system activity following the removal of the alpha-2 adrenergic agonist's suppressive effect. To minimize withdrawal risk, the infusion should be gradually tapered rather than abruptly stopped, typically reducing the rate by 20-25% every 6-8 hours while monitoring for withdrawal symptoms. In patients who develop significant withdrawal, clonidine (an oral alpha-2 agonist) may be used as a transitional agent. Healthcare teams should have a tapering plan in place before initiating prolonged dexmedetomidine infusions.
Dexmedetomidine EQL Pharma, Precedex, and Dexdor all contain the same active substance—dexmedetomidine hydrochloride—and are considered therapeutically equivalent. Precedex (manufactured by Pfizer/Hospira) was the first brand-name dexmedetomidine product approved in the United States, while Dexdor (manufactured by Orion Pharma) was the originator product approved in Europe. Dexmedetomidine EQL Pharma is a generic formulation produced by EQL Pharma that has met the same regulatory standards for quality, safety, and efficacy as the originator products. Generic medicines undergo rigorous bioequivalence testing to demonstrate that they produce the same blood levels of the active substance as the reference product, ensuring equivalent clinical effects.
Continuous monitoring throughout dexmedetomidine infusion is essential and should include: continuous ECG monitoring for heart rate, rhythm, and conduction abnormalities; continuous pulse oximetry for oxygen saturation; arterial blood pressure monitoring (invasive or non-invasive at frequent intervals); regular sedation depth assessment using a validated tool such as the Richmond Agitation-Sedation Scale (RASS) or Riker Sedation-Agitation Scale (SAS); respiratory rate monitoring; and periodic blood glucose checks, as both hyperglycemia and hypoglycemia can occur. Monitoring should continue for a period after discontinuation of the infusion (typically 1-2 hours) as rebound sympathetic activation may occur. Resuscitation equipment, atropine, and vasopressors should be immediately available at the bedside.
References
- European Medicines Agency (EMA). Dexmedetomidine Summary of Product Characteristics. Last updated 2025. Available from: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Precedex (Dexmedetomidine Hydrochloride) Prescribing Information. Revised 2024. Available from: www.accessdata.fda.gov
- Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU (PADIS Guidelines). Critical Care Medicine. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299
- Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials (MIDEX and PRODEX). JAMA. 2012;307(11):1151-1160. doi:10.1001/jama.2012.304
- Shehabi Y, Howe BD, Bellomo R, et al. Early Sedation with Dexmedetomidine in Critically Ill Patients (SPICE III). New England Journal of Medicine. 2019;380(26):2506-2517. doi:10.1056/NEJMoa1904710
- Reade MC, Eastwood GM, Bellomo R, et al. Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium (DahLIA). JAMA. 2016;315(14):1460-1468. doi:10.1001/jama.2016.2707
- Weerink MAS, Struys MMRF, Hannivoort LN, et al. Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. Clinical Pharmacokinetics. 2017;56(8):893-913. doi:10.1007/s40262-017-0507-7
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List. 2023. Available from: www.who.int
- British National Formulary (BNF). Dexmedetomidine Hydrochloride. Available from: bnf.nice.org.uk
- European Society of Intensive Care Medicine (ESICM). Practice Guidelines on Sedation and Analgesia in Critically Ill Adults. 2023.
Editorial Team
This article has been written, reviewed, and approved by the iMedic Medical Editorial Team. Our team comprises licensed specialist physicians with expertise in anesthesiology, critical care medicine, and clinical pharmacology.
Medical Content
Written by iMedic medical writers with specialization in anesthesiology and critical care pharmacology
Medical Review
Reviewed by board-certified specialists in anesthesiology and intensive care medicine
Pharmacological Review
Verified by clinical pharmacologists for drug interactions, dosing accuracy, and safety information
Editorial Standards
Content follows GRADE evidence framework and adheres to international medical editorial standards
All medical information is based on current international guidelines (EMA, FDA, PADIS, ESICM) and peer-reviewed research. Our content is regularly updated to reflect the latest evidence and clinical recommendations. For questions or corrections, please contact our editorial team.